Efficacy of zoledronic acid treatment in Paget disease of bone

Baykan, Emine Kartal; Saygili, Lutfiye Fusun; Erdoğan, Mehmet; Çetinkalp, Şevki; Özgen, A. Gökhan; Yılmaz, Caner

doi:10.1007/s00198-014-2752-z

Cited by 14 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bisphosphonates are widely used as a first‐line treatment for osteoporosis (Grey & Reid, ), preventing bone fracture. Additionally, bisphosphonates have been exploited for their antiproliferative and pro‐apoptotic effects on tumor cells and have been used for the treatment of Paget's disease, breast cancer, bone metastasis, multiple myeloma, and primary hyperparathyroidism (Baykan et al., ; Khan, Grey, & Shoback, ; Pavlakis, Schmidt, & Stockler, ). As the prevalence of osteoporosis has increased, the number of patients suffering from bisphosphonate‐associated osteonecrosis of the jaw (BRONJ) has also increased.…”

Section: Discussionmentioning

confidence: 99%

Effects of locally administered rhBMP‐2 and bisphosphonate on bone regeneration in the rat fibula

Cha

Nam

et al. 2018

Oral Diseases

View full text Add to dashboard Cite

Absorbable collagen sponges with rhBMP-2 were advantageous in that there was no remaining graft material and that the bone was remodeled to resemble the existing fibula. The local application of bisphosphonate promoted new bone formation, particularly when used at high concentrations. High-concentration bisphosphonate induced new bone formation comparable to rhBMP-2 with lesser remaining bone material.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of locally administered rhBMP‐2 and bisphosphonate on bone regeneration in the rat fibula

Cha

Nam

et al. 2018

Oral Diseases

View full text Add to dashboard Cite

show abstract

“…in their retrospective study of 12 patients showed that remission occurred at 6 months and was sustained till 18 months following a single dose of intravenous ZA. [14] Tucci studied the effect of ZA in 14 patients with PDB who had previously received other BPs but had either failed to achieve remission or to maintain it for more than 12 months. Treatment with ZA resulted in remission in 13 out of 14 patients, lasting from 12 to 60 months.…”

Section: Discussionmentioning

confidence: 99%

Response to zoledronic acid in patients with active Paget's disease of bone: A retrospective study

Durgia

Sahoo

Kamalanathan

et al. 2019

Indian J Endocr Metab

View full text Add to dashboard Cite

Background: Traditionally, bisphosphonates are used to treat active Paget's disease of bone (PDB). Intravenous zoledronic acid (ZA) is the most effective treatment option leading to sustained remission. Objective: The primary objective of this study was to analyze the effect of intravenous ZA in patients with active PDB in a tertiary care center of India. Materials and Methods: Retrospective data of 13 patients with active PDB who received a single dose of 4 mg intravenous ZA at our institute from January 2011 to June 2017 were reviewed. Response to therapy was monitored clinically, biochemically by serum alkaline phosphatase (ALP), and scintigraphically by 99m-Technetium methylene diphosphonate bone scan. Results: All of our patients reported relief of bone pain. The mean duration of follow-up in our study was 35.2 ± 16.8 months. Serum ALP levels reduced significantly from 1190.9 ± 666.1 IU/L ( n = 13) at baseline to 200.5 ± 68.4 IU/L ( n = 13) at 6 months ( P < 0.001). ALP level at 1 year was 174 ± 33.6 IU/L ( n = 12), which remained stable till 36 months at 176.5 ± 50 IU/L ( n = 8). This indicates that remission achieved by 6 months post ZA is sustained for at least 3 years. Scintigraphic ratio reduced from 9.6 [interquartile range (IQR) 5.25–18.2] at baseline to 2.7 (IQR 1.20–4.05) at follow-up ( P < 0.001). Similarly, scintigraphic index of involvement reduced from 9.9 (IQR 5.6–28.5) at baseline to 3 (IQR 2–4) at follow-up ( P = 0.018). Conclusion: A 4 mg single dose of intravenous ZA results in clinical, biochemical, and scintigraphic response that is sustained for at least 3 years.

show abstract

“…Пред-почтение в терапии заболевания отдается бисфосфонатам в силу их избирательного действия на костную ткань и длительного сохранения стойкого эффекта [28][29][30][31][32]. Таким образом, двукрат-ное введение золедроновой кис-лоты пациентке с КБП позво-лило достичь низкого уровня активности заболевания, что согласуется с данными других авторов [33][34][35][36], и провести артропластику тазобедренного сустава. Врачам, работающим с костной патологией, надо знать об этом заболевании вви-ду его высокой распространен-ности, поскольку своевремен-ная терапия позволяет избежать прогрессирования болезни, раз-вития ее осложнений и потреб-ности в высокотехнологичной медицинской помощи.…”

Section: пациент а 49 лет в 2004 г (в возрасте 37 лет) по-явилисьunclassified

Diagnostic Aspects of Paget’s Disease of Bone in Clinical Practice

Башкова¹,

Николаев²,

Безлюдная³

et al. 2017

rsp

View full text Add to dashboard Cite

Efficacy of zoledronic acid treatment in Paget disease of bone

Abstract: We recommend zoledronic acid in the first-line treatment of Paget disease of bone in achieving and maintaining remission.

Cited by 14 publications

References 8 publications

Effects of locally administered rhBMP‐2 and bisphosphonate on bone regeneration in the rat fibula

Effects of locally administered rhBMP‐2 and bisphosphonate on bone regeneration in the rat fibula

Response to zoledronic acid in patients with active Paget's disease of bone: A retrospective study

Diagnostic Aspects of Paget’s Disease of Bone in Clinical Practice

Contact Info

Product

Resources

About